Laurion Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Laurion Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-9,270	Closed	-$635K	–	630
2024 Q2	$635K	Buy	+9,270	New	+$643K	0.01%	341
2020 Q4	–	Sell	-175,000	Closed	-$4.49M	–	1022
2020 Q3	$4.49M	Buy	+175,000	New	+$3.99M	0.05%	229
2020 Q2	–	Sell	-150,000	Closed	-$2.31M	–	1230
2020 Q1	$2.31M	Buy	+150,000	New	+$3.26M	0.03%	335
2018 Q1	–	Sell	-226,160	Closed	-$3.27M	–	1764
2017 Q4	$3.27M	Sell	226,160 -323,840	-59%	-$5M	0.02%	650
2017 Q3	$8.68M	Buy	+550,000	New	+$8.07M	0.04%	352
2016 Q2	–	Sell	-7,400	Closed	-$206K	–	1066
2016 Q1	$206K	Buy	7,400 +3,100	+72%	+$103K	﹤0.01%	680
2015 Q4	$231K	Sell	4,300 -91,400	-96%	-$4.61M	﹤0.01%	792
2015 Q3	$3.83M	Buy	+95,700	New	+$3.12M	0.04%	270

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Laurion Capital Management's ITCI Position: Q3 2024 in Review

Laurion Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 9,270 shares — an estimated $635K sold.

Laurion Capital Management first reported a position in ITCI in Q3 2015 and held it in 8 quarters. The position peaked at $8.68M in Q3 2017. 354 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Laurion Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
Laurion Capital Management sold 9,270 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $635K.
Laurion Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 8 quarters.
Laurion Capital Management's Intra-Cellular Therapies Inc. position peaked at $8.68M in Q3 2017.
354 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.